🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD.
Register free to view.
Security Profile
- Security Type
- Common Stock
- CUSIP
- 774374409 (prev. 774374300 )
- Market Cap
- Micro Cap
- Previous Name
- Rockwell Medical Technologies, Inc.
Business: Rockwell Medical, Inc., is a biopharmaceutical company targeting end-stage renal disease and chronic kidney disease. Rockwell Medical's exclusive renal drug therapies support disease management initiatives to improve the quality of life and care of dialysis patients and are intended to deliver safe and effective therapy, while decreasing drug administration costs and improving patient convenience. Rockwell Medical's anemia drug Triferic is the only FDA-approved product indicated for iron replacement and maintenance of hemoglobin in hemodialysis patients.
Notes: June 29, 2026 -- Rockwell Medical, Inc., today announced that its Board of Directors (the "Board") has authorized a 1-for-10 reverse split of the Company's issued and outstanding common stock (the "Reverse Stock Split"). The Board received approval at the Company's Annual Meeting of Stockholders on June 12, 2026 to approve and adopt an amendment to the Company's Certificate of Incorporation to effect a reverse stock split of the Company's common stock. The Reverse Stock Split will become effective at 12:01 a.m. EDT on July 1, 2026. The Company's common stock will continue to trade under the symbol "RMTI" on the Nasdaq Capital Market. The new CUSIP number following the Reverse Stock Split will be 774374409.
Company Contact
- CEO
- Mark Strobeck
- CFO
- Russell L. Skibsted
- Headquarters
- 30142 Wixom Road, Wixom, MI 48393
- Phone
- 248-960-9009 · Toll-Free 800-449-3353
- Fax
- 248-960-9119
- Investor Relations
- Heather R. Hunter · 248-532-1362 · IR@rockwellmed.com